Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Meeting Reports

Subcategories:EULAR/OtherOther ACR meetings

Phase 2 Study Shows Promising Results for Deucravacitinib in PsA

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.

Baricitinib Promising for Juvenile Idiopathic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  July 19, 2022

In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

Predicting the Future: Prognostication in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  July 19, 2022

A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.

Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  July 15, 2022

Dr. Jacob van Laar took a deep dive into the what defines difficult-to-treat rheumatoid arthritis & how to approach these patients during EULAR 2022.

Spine School: Axial Manifestations of Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  July 15, 2022

This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.

Never Too Late: Late-Breaking Abstracts Create Excitement

Jason Liebowitz, MD, FACR  |  July 15, 2022

EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…

Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More

Jason Liebowitz, MD, FACR  |  July 15, 2022

In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.

Challenges in Reproductive Health in Rheumatic Disease

Keri Losavio & Julie Nusbaum, MD  |  July 11, 2022

In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.

ACR-FDA Summit Focuses on Study Design, Safety Considerations

Vanessa Caceres  |  June 21, 2022

Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.

Kidney Pathology for the Rheumatologist: Tips from an Expert

Samantha C. Shapiro, MD  |  June 18, 2022

Renal biopsy is a valuable tool for the accurate diagnosis and management of patients with kidney involvement due to rheumatic disease. Agnes B. Fogo, MD, shared her expertise on renal pathology and insights into what rheumatologists should know, during a session at the 2022 ACR Education Exchange.

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences